Drugs / GV-971
GV-971
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03715114 | Oct → Nov 2018 | — | Shanghai Greenvalley Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02986529 | Nov 2016 → Feb 2017 | — | Shanghai Greenvalley Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01453569 | Oct 2011 → Aug 2013 | Alzheimer disease | Shanghai Greenvalley Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02293915 | Apr 2014 → Jun 2018 | Alzheimer disease | Shanghai Greenvalley Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05430867 | Jul 2022 → Jul 2024 | Alzheimer disease | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GV-971 | “Sodium oligomannate (GV-971), a marine-derived oligosaccharide, is a novel agent that may improve cognition in AD patients.” PMID 32928279 ↗ Sep 2020 |
| Known as | Sodium oligo-mannurarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02293915 ↗ |
| Known as | sodium oligomannate | “Sodium oligomannate (GV-971), a marine-derived oligosaccharide, is a novel agent that may improve cognition in AD patients.” PMID 32928279 ↗ Sep 2020 |
| Modality | Oligonucleotide (other) | “Sodium oligomannate (GV-971), a marine-derived oligosaccharide, is a novel agent that may improve cognition in AD patients.” PMID 32928279 ↗ Sep 2020 |
| Route | Oral | “sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks” NCT01453569 ↗ |